3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Hematologic Neoplasms
1
Febrile Neutropenia
1
Interventions
pegylated granulocyte colony-stimulating factor
3
pegfilgrastim
3
Vancomycin
3
Linezolid
2
Filgrastim
2
ceftolozane, tazobactam drug combination
1
Teicoplanin
1
Sodium Chloride
1
Piperacillin, Tazobactam Drug Combination
1
N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
1
Meropenem
1
Itraconazole
1
Cefepime
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Febrile Neutropenia
×
ceftolozane, tazobactam drug combination
×
Clear all
NCT05061654
2023-08-14
CEF-10
Hamad Medical Corporation
Phase 4
Withdrawn